ProMIS Neurosciences, Inc. Annual report [Section 13 and 15(d), not S-K Item 405]

NET LOSS PER SHARE - Outstanding potentially dilutive common shares (Details) - shares	12 Months Ended
	Dec. 31, 2025	Dec. 31, 2024
NET LOSS PER SHARE
Dilutive common shares equivalents excluded from computation of diluted net loss per share for periods presented because including them would have been antidilutive	2,745,201	2,342,195
Employee Stock Option
NET LOSS PER SHARE
Dilutive common shares equivalents excluded from computation of diluted net loss per share for periods presented because including them would have been antidilutive	180,827	142,978
Warrants.
NET LOSS PER SHARE
Dilutive common shares equivalents excluded from computation of diluted net loss per share for periods presented because including them would have been antidilutive	2,564,332	2,199,175
Deferred Share Units
NET LOSS PER SHARE
Dilutive common shares equivalents excluded from computation of diluted net loss per share for periods presented because including them would have been antidilutive	42	42